Insilico Medicine and SK Biopharmaceuticals launched an AI-based neuroimmune drug collaboration that could generate up to $2.5 billion in value for Insilico’s efforts. Under the deal, Insilico will apply its Pharma.AI platform—covering target validation, generative chemistry, and molecule optimization—to discover and design candidates for neuroimmune indications originating from SK. SK will steer late-stage development and commercialization for programs that emerge from the collaboration, using its clinical capabilities in neuroimmune disorders within the CNS franchise. The partnership extends SK beyond its epilepsy-focused momentum and leverages its in-house development footprint. For AI-first drug discovery companies and platform investors, the agreement reflects growing demand from large biotech for outsourced discovery engines that can hand off development-ready candidates with faster iteration cycles.